PFIZER (PHMP) for Transparency Documents Files

GOOGLE A Serious Violators of the 1st Amendment
FACEBOOK A Serious Violators of the 1st Amendment
YOUTUBE A Serious Violators of the 1st Amendment
TWITTER A Serious Violators of the 1st Amendment
4CM_Telegram-thumbs-up-400w-480h.fw
Internet_Archive_thumbs-up-400w-480h.fw
bitchute-thumbs-up-400w-480h.fw
Gab_thumbs-up-400w-480h.fw
parler-thumbs-up-400w-480h.fw

Remarks: PFIZER (PHMP) for Transparency Documents Files: PHMP is non-profit, made up of public health professionals, medical professionals, scientists, and journalists exists solely to obtain and disseminate the data relied upon by the FDA to license COVID-19 vaccines. The PHMP organization takes no position on the data other than that it should be made publicly available to allow independent experts to conduct their own review and analyses. Any data PHMP receives is made public. FULL STORY HERE: https://www.4cmitv.com/2022/05/08/pfizer-phmp-for-transparency-documents-files/


BACKGROUND HEADLINES: Public Health and Medical Professionals (PHMP) for Transparency PFIZER Documents

File NameDate ProducedFile SizeLink
FDA-CBER-2021-5683-0123168-to-0126026_125742_S1_M5_c4591001-A-D-adva.zip (.xpt)May 2, 20227 MBDownload
FDA-CBER-2021-5683-0066701-to-0123167_125742_S1_M5_c4591001-A-D-adfacevd.zip (.xpt)May 2, 202281 MBDownload
FDA-CBER-2021-5683-0059000 to -0065773_125742_S1_M5_c4591001-A-D-adcevd.zip (.xpt)May 2, 20229 MBDownload
FDA CBER 2021 5683 0065774 to 0066700_125742_S1_M5_c4591001 A D addv.xptMay 2, 202244 MBDownload
FDA CBER 2021 5683 0058955 to 0058999_125742_S1_M5_bnt162 01 S define 2 0 0.xslMay 2, 2022183 KBDownload
FDA CBER 2021 5683 0058795 to 0058828_125742_S1_M5_bnt162 01 A define 2 0 0.xslMay 2, 2022183 KBDownload
FDA CBER 2021 5683 0058829 to 0058954_125742_S1_M5_bnt162 01 S define.xmlMay 2, 2022985 KBDownload
FDA CBER 2021 5683 0058615 to 0058652_125742_S1_M5_c4591001 S Supp define.xmlMay 2, 2022300 KBDownload
FDA CBER 2021 5683 0058653 to 0058675_125742_S1_M5_c4591001 S Supp define 2 0 0.xslMay 2, 2022183 KBDownload
FDA CBER 2021 5683 0058676 to 0058794_125742_S1_M5_bnt162 01 A define.xslMay 2, 2022828 KBDownload
FDA CBER 2021 5683 0058595 to 0058614_125742_S1_M5_c4591001 S define 2 0 0.xslMay 2, 2022183 KBDownload
FDA CBER 2021 5683 0058459 to 0058478_125742_S1_M5_c4591001 A Supp define 2 0 0.xslMay 2, 2022183 KBDownload
FDA CBER 2021 5683 0058479 to 0058594_125742_S1_M5_c4591001 S define.xmlMay 2, 2022904 KBDownload
FDA CBER 2021 5683 0058316 to 0058458_125742_S1_M5_c4591001 A Supp define.xmlMay 2, 2022692 KBDownload
125742_S1_M5_CRF_c4591001 1006 10061098.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1006 10061176.pdfMay 2, 20223 MBDownload
125742_S1_M5_CRF_c4591001 1006 10061094.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1006 10061040.pdfMay 2, 20224 MBDownload
125742_S1_M5_CRF_c4591001 1006 10061052.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1006 10061020.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1005 10051411.pdfMay 2, 20221 MBDownload
125742_S1_M5_CRF_c4591001 1005 10051387.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1005 10051293.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1005 10051347.pdfMay 2, 20221 MBDownload
125742_S1_M5_CRF_c4591001 1005 10051214.pdfMay 2, 20221 MBDownload
125742_S1_M5_CRF_c4591001 1005 10051054.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1005 10051069.pdfMay 2, 20221 MBDownload
125742_S1_M5_CRF_c4591001 1003 10031038.pdfMay 2, 20223 MBDownload
125742_S1_M5_CRF_c4591001 1001 10011100.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1001 10011135.pdfMay 2, 20221 MBDownload
125742_S1_M5_CRF_c4591001 1001 10011093.pdfMay 2, 20223 MBDownload
125742_S1_M5_CRF_c4591001 1005 10051047.pdfMay 2, 20221 MBDownload
125742_S1_M5_CRF_c4591001 1003 10031197.pdfMay 2, 20221 MBDownload
125742_S1_M5_CRF_c4591001 1003 10031207.pdfMay 2, 20221 MBDownload
125742_S1_M5_CRF_c4591001 1003 10031186.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1003 10031149.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1003 10031113.pdfMay 2, 20223 MBDownload
125742_S1_M5_CRF_c4591001 1003 10031111.pdfMay 2, 20222 MBDownload
125742_S1_M5_CRF_c4591001 1003 10031065.pdfMay 2, 20223 MBDownload
125742_S1_M5_bnt162 01 S acrf.pdfMay 2, 20221 MBDownload
125742_S1_M5_bnt162 01 A adrg.pdfMay 2, 2022891 KBDownload
125742_S1_M5_c4591001 S csdrg.pdfMay 2, 20221 MBDownload
125742_S1_M5_c4591001 S Supp acrf.pdfMay 2, 20223 MBDownload
125742_S1_M5_c4591001 S acrf.pdfMay 2, 20223 MBDownload
125742_S1_M5_bnt162 01 S csdrg.pdfMay 2, 20221 MBDownload
125742_S1_M5_5351_c4591001 interim mth6 sponsor signature.pdfMay 2, 202212 MBDownload
125742_S1_M5_5351_c4591001 interim mth6 sample crf.pdfMay 2, 20225 MBDownload
125742_S1_M5_5351_c4591001 interim mth6 randomization sensitive.pdfMay 2, 202265 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 sample crf.pdfMay 2, 20229 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 report body.pdfMay 2, 202242 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 protocol deviations.pdfMay 2, 20221 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 protocol.pdfMay 2, 202210 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 patient batches.pdfMay 2, 20223 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 notes for reader.pdfMay 2, 20221 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 synopsis.pdfMay 2, 20224 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 sponsor signature.pdfMay 2, 20222 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 sponsor personnel list.pdfMay 2, 20222 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 sap.pdfMay 2, 20223 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 lab measurements.pdfMay 2, 202291 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 discontinued patients.pdfMay 2, 20222 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 demographics.pdfMay 2, 20222 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 compliance.pdfMay 2, 20227 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 adverse events.pdfMay 2, 20227 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 investigators.pdfMay 2, 20226 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 invest signature.pdfMay 2, 2022634 KBDownload
125742_S1_M5_5351_bnt162 01 interim3 iec irb.pdfMay 2, 20221 MBDownload
125742_S1_M5_5351_bnt162 01 interim3 excluded patients.pdfMay 2, 20222 MBDownload
125742_S1_M5_5351_bnt162 01_10075.pdfMay 2, 20222 MBDownload
125742_S1_M5_5351_bnt162 01_10010.pdfMay 2, 20221 MBDownload
125742_S1_M5_5351_bnt162 01_20215.pdfMay 2, 20222 MBDownload
125742_S1_M5_5351_bnt162 01_20242.pdfMay 2, 20222 MBDownload
125742_S1_M5_5351_bnt162 01_20116.pdfMay 2, 20222 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-protocol-deviations.pdfApril 1, 20221 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-iec-irb-consent-form.pdfApril 1, 20228 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-invest-signature.pdfApril 1, 2022677 KBDownload
125742_S1_M5_5351_c4591001-fa-interim-demographics.pdfApril 1, 202228 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-audit-certificates.pdfApril 1, 2022869 KBDownload
125742_S1_M5_5351_c4591001-interim-mth6-invest-signature.pdfApril 1, 20221 MBDownload
reissue_5.3.6 postmarketing experience.pdfApril 1, 2022958 KBDownload
125742_S1_M5_5351_c4591001-interim-mth6-demographics.pdfApril 1, 202228 MBDownload
125742_S1_M5_5351_c4591001-interim-mth6-audit-certificates.pdfApril 1, 20221 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-sponsor-signature.pdfApril 1, 20222 MBDownload
125742_S1_M5_5351_c4591001-interim-mth6-adverse-events-sensitive.pdfApril 1, 20221 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-sample-crf.pdfApril 1, 20225 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-randomization-sensitive.pdfApril 1, 202259 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-randomization.pdfApril 1, 20222 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-publications.pdfApril 1, 202210 MBDownload
125742_S1_M1_priority-review-request.pdfMarch 24, 20222 MBDownload
FDA-CBER-2021-5683-0023924_125742_S1_M5_c4591001-A-report-cci-chf.xlsxMarch 1, 202210 KBDownload
FDA-CBER-2021-5683-0023926_125742_S1_M5_c4591001-A-report-cci-dementia.xlsxMarch 1, 20229 KBDownload
FDA-CBER-2021-5683-0023878_125742_S1_M5_c4591001-A-report-cci-aids-hiv.xlsxMarch 1, 202223 KBDownload
FDA-CBER-2021-5683-0023895 to -0023915_125742_S1_M5_c4591001-A-report-cci-any-malignancy.xlsxMarch 1, 202235 KBDownload
FDA-CBER-2021-5683-0023919 to -0023921_125742_S1_M5_c4591001-A-report-cci-cerebrovascular.xlsxMarch 1, 202212 KBDownload
FDA-CBER-2021-5683-0023550 to -0023569_125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.xlsxMarch 1, 202222 KBDownload
FDA-CBER-2021-5683-0023711 to -0023875_125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.xlsxMarch 1, 202284 KBDownload
FDA-CBER-2021-5683-0023500 to -0023507_125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.xlsxMarch 1, 202229 KBDownload
FDA-CBER-2021-5683-0023523 to -0023538_125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.xlsxMarch 1, 202218 KBDownload
FDA-CBER-2021-5683-0023540_125742_S1_M5_c4591001-A-comorbidity-categories.xlsxMarch 1, 202219 KBDownload
FDA-CBER-2021-5683-0023979 to -0023980_125742_S1_M5_c4591001-A-report-cci-renal.xlsxMarch 1, 202211 KBDownload
FDA-CBER-2021-5683-0023983 to -0023984_125742_S1_M5_c4591001-A-report-cci-rheumatic.xlsxMarch 1, 202224 KBDownload
FDA-CBER-2021-5683-0023987_125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.xlsxMarch 1, 202221 KBDownload
FDA-CBER-2021-5683-0023971 to -0023972_125742_S1_M5_c4591001-A-report-cci-periph-vasc.xlsxMarch 1, 202212 KBDownload
FDA-CBER-2021-5683-0023975 to -0023976_125742_S1_M5_c4591001-A-report-cci-pulmonary.xlsxMarch 1, 202212 KBDownload
FDA-CBER-2021-5683-0023963_125742_S1_M5_c4591001-A-report-cci-mild-liver.xlsxMarch 1, 202210 KBDownload
FDA-CBER-2021-5683-0023965_125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.xlsxMarch 1, 20229 KBDownload
FDA-CBER-2021-5683-0023967_125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.xlsxMarch 1, 20229 KBDownload
FDA-CBER-2021-5683-0023955 to -0023958_125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.xlsxMarch 1, 202214 KBDownload
FDA-CBER-2021-5683-0023960_125742_S1_M5_c4591001-A-report-cci-mi.xlsxMarch 1, 20229 KBDownload
FDA-CBER-2021-5683-0023932_125742_S1_M5_c4591001-A-report-cci-hemiplegia.xlsxMarch 1, 202210 KBDownload
FDA-CBER-2021-5683-0023936 to -0023937_125742_S1_M5_c4591001-A-report-cci-leukemia.xlsxMarch 1, 202212 KBDownload
FDA-CBER-2021-5683-0023944 to -0023950_125742_S1_M5_c4591001-A-report-cci-lymphoma.xlsxMarch 1, 202217 KBDownload
FDA-CBER-2021-5683-0023928_125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.xlsxMarch 1, 20229 KBDownload
FDA-CBER-2021-5683-0023930_125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.xlsxMarch 1, 202210 KBDownload
FDA-CBER-2021-5683-0023455 to -0023486_125742_S1_M5_c4591001-A-define-2-0-0.xslMarch 1, 2022183 KBDownload
FDA-CBER-2021-5683-0023490 to -0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsxMarch 1, 202213 KBDownload
FDA-CBER-2021-5683-0023490 to -0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsxMarch 1, 202213 KBDownload
FDA-CBER-2021-5683-0022618 to -0022691_125742_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-sas.txtMarch 1, 202275 KBDownload
FDA-CBER-2021-5683-0023007 to -0023031_125742_S1_M5_c4591001-A-P-adsympt-sas.txtMarch 1, 202243 KBDownload
FDA-CBER-2021-5683-0023032 to -0023065_125742_S1_M5_c4591001-A-P-adva-sas.txtMarch 1, 202245 KBDownload
FDA-CBER-2021-5683-0022793 to -0022866_125742_S1_M5_c4591001-A-P-adsl-s005-demo-all-p3-saf-sas.txtMarch 1, 202275 KBDownload
FDA-CBER-2021-5683-0022867 to -0023006_125742_S1_M5_c4591001-A-P-adsl-sas.txtMarch 1, 2022197 KBDownload
FDA-CBER-2021-5683-0022692 to -0022765_125742_S1_M5_c4591001-A-P-adsl-demo-7d-wwo-eval-eff-sas.txtMarch 1, 202275 KBDownload
FDA-CBER-2021-5683-0022766 to -0022792_125742_S1_M5_c4591001-A-P-adsl-fu-d2-p3-saf-sas.txtMarch 1, 202229 KBDownload
FDA-CBER-2021-5683-0022326 to -0022345_125742_S1_M5_c4591001-A-P-adcevd-sas.txtMarch 1, 202227 KBDownload
FDA-CBER-2021-5683-0022063 to -0022135_125742_S1_M5_c4591001-A-P-adce-s010-lr-p3-saf-sas.txtMarch 1, 202272 KBDownload
FDA-CBER-2021-5683-0022136 to -0022325_125742_S1_M5_c4591001-A-P-adce-s020-se-p3-saf-sas.txtMarch 1, 2022193 KBDownload
FDA-CBER-2021-5683-0022601 to -0022617_125742_S1_M5_c4591001-A-P-admh-sas.txtMarch 1, 202224 KBDownload
FDA-CBER-2021-5683-0022041 to -0022053_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-sas.txtMarch 1, 202219 KBDownload
FDA-CBER-2021-5683-0022054 to -0022062_125742_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-pd1-aai-sas.txtMarch 1, 202212 KBDownload
FDA-CBER-2021-5683-0022561 to -0022567_125742_S1_M5_c4591001-A-P-adds-sas.txtMarch 1, 202211 KBDownload
FDA-CBER-2021-5683-0022568 to -0022600_125742_S1_M5_c4591001-A-P-adfacevd-sas.txtMarch 1, 202249 KBDownload
FDA-CBER-2021-5683-0022346 to -0022364_125742_S1_M5_c4591001-A-P-adcm-sas.txtMarch 1, 202232 KBDownload
FDA-CBER-2021-5683-0022365 to -0022560_125742_S1_M5_c4591001-A-P-adds-s002-all-p3-rand-sas.txtMarch 1, 2022156 KBDownload
125742_S1_M5_CRF_c4591001-1085-10851216March 1, 20221 MBDownload
FDA-CBER-2021-5683-0021981 to -0022027_125742_S1_M5_c4591001-A-P-adc19ef-sasMarch 1, 202281 KBDownload
FDA-CBER-2021-5683-0022028 to -0022040_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-sg-eval-sasMarch 1, 202220 KBDownload
FDA-CBER-2021-5683-0021930 to -0021943_125742_S1_M5_c4591001-A-P-adae-s092-cr-cut-p3x-saf-sasMarch 1, 202215 KBDownload
FDA-CBER-2021-5683-0021944 to -0021963_125742_S1_M5_c4591001-A-P-adae-sasMarch 1, 202235 KBDownload
FDA-CBER-2021-5683-0021964 to -0021980_125742_S1_M5_c4591001-A-P-adae-vax-tier2-p3-saf-sasMarch 1, 202218 KBDownload
FDA-CBER-2021-5683-0021902 to -0021915_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf2-sasMarch 1, 202215 KBDownload
FDA-CBER-2021-5683-0021916 to -0021929_125742_S1_M5_c4591001-A-P-adae-s092-all-unb-p3-saf-sasMarch 1, 202215 KBDownload
125742_S1_M5_CRF_c4591001-1085-10851246.pdfMarch 1, 20221 MBDownload
FDA-CBER-2021-5683-0021888 to -0021901_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf1-sas.txtMarch 1, 202214 KBDownload
125742_S1_M5_c4591001-T-S-roadmap.pdfMarch 1, 2022703 KBDownload
125742_S1_M5_c4591001-T-S-final-reacto-tables-track.pdfMarch 1, 20222 MBDownload
125742_S1_M5_c4591001-A-report-cci-renal.pdfMarch 1, 2022629 KBDownload
125742_S1_M5_c4591001-A-report-cci-rheumatic.pdfMarch 1, 2022629 KBDownload
125742_S1_M5_CRF_c4591001-1085-10851129.pdfMarch 1, 20222 MBDownload
125742_S1_M5_CRF_c4591001-1085-10851018.pdfMarch 1, 20222 MBDownload
125742_S1_M5_CRF_c4591001-1085-10851116.pdfMarch 1, 20221 MBDownload
125742_S1_M5_c4591001-T-S-updated-reacto-tlf.pdfMarch 1, 202217 MBDownload
125742_S1_M5_c4591001-T-S-suppl-arg.pdfMarch 1, 2022738 KBDownload
125742_S1_M5_c4591001-T-S-summary-differences-csr-vs-update.pdfMarch 1, 2022667 KBDownload
125742_S1_M5_c4591001-A-report-cci-lymphoma.pdfMarch 1, 2022640 KBDownload
125742_S1_M5_c4591001-A-report-cci-hemiplegia.pdfMarch 1, 2022626 KBDownload
125742_S1_M5_c4591001-A-report-cci-leukemia.pdfMarch 1, 2022631 KBDownload
125742_S1_M5_c4591001-A-report-cci-periph-vasc.pdfMarch 1, 2022632 KBDownload
125742_S1_M5_c4591001-A-report-cci-pulmonary.pdfMarch 1, 2022630 KBDownload
125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.pdfMarch 1, 2022625 KBDownload
125742_S1_M5_c4591001-A-report-cci-mild-liver.pdfMarch 1, 2022628 KBDownload
125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.pdfMarch 1, 2022626 KBDownload
125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.pdfMarch 1, 2022636 KBDownload
125742_S1_M5_c4591001-A-report-cci-mi.pdfMarch 1, 2022624 KBDownload
125742_S1_M5_c4591001-A-report-cci-any-malignancy.pdfMarch 1, 2022670 KBDownload
125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.pdfMarch 1, 2022846 KBDownload
125742_S1_M5_c4591001-A-report-cci-aids-hiv.pdfMarch 1, 2022629 KBDownload
125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.pdfMarch 1, 2022607 KBDownload
125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.pdfMarch 1, 2022627 KBDownload
125742_S1_M5_c4591001-A-comorbidity-categories.pdfMarch 1, 2022637 KBDownload
125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.pdfMarch 1, 2022626 KBDownload
125742_S1_M5_c4591001-A-report-cci-chf.pdfMarch 1, 2022628 KBDownload
125742_S1_M5_c4591001-A-report-cci-dementia.pdfMarch 1, 2022626 KBDownload
125742_S1_M5_c4591001-A-report-cci-cerebrovascular.pdfMarch 1, 2022632 KBDownload
125742_S1_M5_5351_c4591001-fa-interim-oversight-committees.pdfMarch 1, 20222 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-lab-measurements-sensitive.pdfMarch 1, 20225 MBDownload
125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.pdfMarch 1, 2022620 KBDownload
125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.pdfMarch 1, 2022634 KBDownload
125742_S1_M5_c4591001-A-adrg.pdfMarch 1, 20222 MBDownload
125742_S1_M5_c4591001-A-bmi-12-15-scale.pdfMarch 1, 2022627 KBDownload
125742_S1_M5_5351_c4591001-interim-mth6-protocol.pdfMarch 1, 202237 MBDownload
125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.pdfMarch 1, 2022602 KBDownload
125742_S1_M5_5351_c4591001-interim-mth6-oversight-committees.pdfMarch 1, 202213 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-protocol.pdfMarch 1, 202231 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-excluded-patients.pdfMarch 1, 20222 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-errata.pdfMarch 1, 20222 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-efficacy-response.pdfMarch 1, 20222 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-compliance-sensitive.pdfMarch 1, 20221 MBDownload
125742_S1_M5_5351_c4591001-ad-hoc-label-tables.pdfMarch 1, 2022889 KBDownload
125742_S1_M5_5351_c4591001-fa-interim-compliance.pdfMarch 1, 20222 MBDownload
125742_S1_M4_4223_R-20-0072.pdfMarch 1, 20225 MBDownload
125742_S1_M4_4223_185350.pdfMarch 1, 20221 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-lab-measurements.pdfMarch 1, 202212 MBDownload
125742_S1_M5_5351_c4591001-fa-interim-excluded-patients-sensitive.pdfMarch 1, 202216 MBDownload
125742_S1_M2_26_pharmkin-written-summary.pdfMarch 1, 20221 MBDownload
125742_S1_M2_24_nonclinical-overview.pdfMarch 1, 20222 MBDownload
125742_S1_M2_26_pharmkin-tabulated-summary.pdfMarch 1, 20221 MBDownload
125742_S1_M2_22_introduction.pdfMarch 1, 2022670 KBDownload
125742_S1_M1_waiver-req-designated-suffix.pdfMarch 1, 20223 MBDownload
125742_S1_M1_us-agent-authorization.pdfMarch 1, 20221 MBDownload
125742_S1_M1_userfee.pdfMarch 1, 2022628 KBDownload
125742_S1_M2_27_synopses-indiv-studies.pdfMarch 1, 20222 MBDownload
125742_S1_M1_trans-of-oblig.pdfMarch 1, 2022717 KBDownload
125742_S1_M2_27_literature-references.pdfMarch 1, 20222 MBDownload
125742_S1_M1_ipsp-agreed-letter.pdfMarch 1, 2022658 KBDownload
125742_S1_M1_financial-cert-3454.pdfMarch 1, 20223 MBDownload
125742_S1_M1_financial-cert-bias.pdfMarch 1, 2022696 KBDownload
125742_S1_M1_fast-track-designation.pdfMarch 1, 2022649 KBDownload
125742_S1_M1_exclusivity-claim.pdfMarch 1, 2022616 KBDownload
125742_S1_M1_cover.pdfMarch 1, 20221 MBDownload
125742_S1_M1_debarment.pdfMarch 1, 2022656 KBDownload
125742_S1_M1_3674.pdfMarch 1, 20225 MBDownload
125742_S1_M1_356h.pdfMarch 1, 2022714 KBDownload
125742_S1_M1_priority-review-request.pdfMarch 1, 20222 MBDownload
CRFs for site 1128.pdfJanuary 31, 202214 MBDownload
CRFs for site 1096.pdfJanuary 18, 202211 MBDownload
CRFs for site 1081.pdfDecember 30, 202113 MBDownload
Supplemental Index 12-22-21.pdfDecember 22, 20212 MBDownload
STN 125742_0_0 Section 2.7.4 summary-clin-safety.pdfDecember 13, 20216 MBDownload
STN 125742_0_0 Section 2.7.3 Summary of Clinical Efficacy.pdfDecember 13, 20213 MBDownload
STN 125742_0_0 Section 2.5 Clinical Overview.pdfDecember 13, 20214 MBDownload
CRFs for site 1055.pdfDecember 13, 20216 MBDownload
BATES-FDA-CBER-2021-5683-0002376_relrec.xptDecember 13, 2021567 KBDownload
BATES-FDA-CBER-2021-5683-0002380_ti.xptDecember 13, 202137 KBDownload
BATES-FDA-CBER-2021-5683-0002379_te.xptDecember 13, 20213 KBDownload
BATES-FDA-CBER-2021-5683-0002378_ta.xptDecember 13, 20218 KBDownload
signed F21-5683 CBER Dec 13 2021 Response Letter.pdfDecember 13, 2021207 KBDownload
BATES-FDA-CBER-2021-5683-0002377_supppr.xptDecember 13, 202172 KBDownload
BATES-FDA-CBER-2021-5683-0002375_addv-sas.txtDecember 13, 20215 KBDownload
BATES-FDA-CBER-2021-5683-0002374_adc19ef-ve-sev-cov-7pd2-wo-eval-sas.txtDecember 13, 20219 KBDownload
BATES-FDA-CBER-2021-5683-0002373_adc19ef-ve-sev-cov-7pd2-eval-sas.txtDecember 13, 20219 KBDownload
BATES-FDA-CBER-2021-5683-0002372_adc19ef-ve-cov-7pd2-eval-sas.txtDecember 13, 20219 KBDownload
Pages 42-289-Section 5.2 – listing-clinical-sites-cvs_Part B.pdfDecember 1, 202114 MBDownload
Pages 42-289-Section 5.2 – listing-clinical-sites-cvs_Part A.pdfDecember 1, 202112 MBDownload
5.2 listing of clinical sites and cvs pages 1-41.pdfNovember 17, 20218 MBDownload
5.2 tabular listing.pdfNovember 17, 20212 MBDownload
5.3.6 postmarketing experience.pdfNovember 17, 2021984 KBDownload
BATES-93_tv.xptNovember 17, 202116 KBDownload
BATES-92_adc19ef-ve-cov-7pd2-wo-eval-sas.txtNovember 17, 20219 KBDownload

PFIZER (PHMP) for Transparency
Large Documents

ZIP FILES
URL: https://www.4cmitv.com/2022/05/08/pfizer-phmp-for-transparency-documents-large-zip-files/

SOURCE:
Public Health and Medical Professionals
(PHMP) for Transparency
Pfizer’s Documents Zip Files https://phmpt.org/multiple-file-downloads/

4CM DISCLAIMER: in publishing this DOES NOT MEAN 4CM is VERIFYING the VERACITY OF THE CONTENT. We are just making you aware of Data. That has been Dropped on the net. to enable facilitate healthy investigations of the truth, which our reader/viewers maybe pursuing 



RELATED

PFIZER (PHMP) for Transparency Documents Large Zip Files https://www.4cmitv.com/2022/05/08/pfizer-phmp-for-transparency-documents-large-zip-files/

 

Unlike many news and information platforms, 4cminews is free to read, and always will be. There is no paywall here. We are independent, not affiliated with nor representing any political party or business organisation. We want the very best for our readers, nothing more, nothing less. Your support will help us continue to provide factual News about world events and Global Agenda’s.

You can contribute here. Thank you.

4cminewswire support independent media service



Hashtags: #4cminewswire, #Pfizer, #PfizerLies, #PeopleDied, #4cminews, #4CM2022MAY08

Tags: 4cminewswire, Pfizer, Pfizer Lies People Died, 4cminews, 4CMiTV, #4CM2022MAY08


SOURCE ACKNOWLEDGEMENTS

Original-Source
Original-Source-Published
Original-Source-URL

SOURCE ACKNOWLEDGEMENTS

Original-Source
Original-Source-Published
Original-Source-URL

MEDIA CLIP PROPERTIES:
Length: (00:00:00:00 minutes)
Size: (xx MB)
Frame-W: 1920
Frame-H: 1080
Frame-Rate kbps: 25.00
Data-Rate kbps

MEDIA CLIP PROPERTIES:
Length: (00:00:00:00 minutes)
Size: (xx MB)
Frame-W: 1280
Frame-H: 0720
Frame-Rate kbps: 25.00
Data-Rate kbps


4cminewswire.com

4cmitv.com

4cminews.com

fourcm.net

4cminewswireGlobal

Global Red Pill News

Churchinperth

Dailybread.com.au

VVANZ

DIOXINNZ

4cmEndTimes

AccVictimsLobby

@4cmtvworld

@4cminews  

FREEDOM VILLAGE Social Media Group

@4cminewswire

GAB Social Media Group

@4cminewsire

Instagram Social Media Group

@4cminews

LinkedIn Social Media Group

@4cmgroup 

MeWe Social Media Group

@4cminewswire 

SAFECHAT Social Media Group

@4cminewswire

WHIZNA Social Media Group

@4cminewswire

YouTube Channel

@GaryGreen4CMiCTV

BitChute Channel

@Freedom4CM

Rumble Channel

@4cmDisclosures

GabTV Channel

@4cminewswire

BrandNewTube Channel

@4cminewswire

A Guide to Home-Based COVID Treatment.
Step-By-Step Doctors’ Plan That Could Save Your Life
DOWNLOAD FREE BOOKLET:
 
An educational resource from The Association of American Physicians and Surgeons
(AAPSonline.org)

Leave a Reply

Your email address will not be published.